Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease - Seite 3

About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 130,000 people of more than 145 nationalities work at Novartis around the world. To learn more, visit www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [e-mail]

References
            [1] https://www.who.int/neglected_diseases/news/fascioliasis-review-provid ...
            [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568335/

# # #

Novartis Media Relations
Central media line: [phone]
E-mail: [e-mail]

Eric Althoff Novartis Global Media Relations [phone] (direct) [phone] (mobile) [e-mail]

Katerina Kontzalis Novartis Communications [phone] (direct) [phone] (Mobile) [e-mail]

Novartis Investor Relations
Central investor relations line: [phone]
E-mail: [e-mail]

Central		North America
Samir Shah	[phone]	Richard Pulik	[phone]
Pierre-Michel Bringer	[phone]	Cory Twining	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]